XORTX Therapeutics Inc.

Stage 4 · Declining · week 16

As of Oct 22, 2026, XORTX Therapeutics is in Stage 4, the downtrend phase, now in week 16 (since Jul 6, 2026). It closed at $0.97, 73.0% below its 52-week high and below its 200-day average, which is falling.

$0.97

+4.18% today

$1.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is XRTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 29w

S4 19w

S4 24w

S4 19w

S4 25w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 29w → S1 9w → S2 1w → S1 1w → S4 19w → S1 1w → S4 4w → S1 2w → S4 24w → S1 5w → S4 19w → S1 2w → S4 25w → S1 9w → S4 16w current

Total tracked: 165 weeks across 15 stage runs.

XRTX among Biotechnology440th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…440	XRTXXORTX Therapeutics Inc.	Stage 4 · wk 16	14	−43.0%

vs 52W High

-73.0%

$0.93 lo$3.59 hi

73.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 16

1w13w26w

Week 16, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-55.6%

200 DMA: $2.18 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.03x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-43.0%

-52.1%

-65.0%

YTD

-66.0%

-73.3%

Scan Membership

Breakout Watch

Latest: 2024-05-08

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 16 · Vol 0.03x

2026-10-21S4

Wk 16 · Vol 0.08x

2026-10-20S4

Wk 16 · Vol 0.09x

2026-10-19S4

Wk 15 · Vol 0.14x

2026-10-16S4

Wk 15 · Vol 0.10x

2026-10-15S4

Wk 15 · Vol 0.14x

2026-10-14S4

Wk 15 · Vol 0.08x

2026-10-13S4

Wk 15 · Vol 0.20x

2026-10-12S4

Wk 14 · Vol 2.02x

2026-10-09S4

Wk 14 · Vol 37.48x

2026-10-08S4

Wk 14 · Vol 37.52x

2026-10-07S4

Wk 14 · Vol 0.08x

Moving averages & range

50 DMA

$1.86

200 DMA

$2.18

52W High

$3.59

52W Low

$0.93

5D Low

$0.93

Resistance levels (recent highs)

20d High

$1.85

60d High

$2.48

120d High

$2.98

250d High

$3.32

Next resistance

+90.9%

to 20d High

ROE

-99.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.3

XORTX Therapeutics: quick answers

What stage is XORTX Therapeutics in?

As of Oct 22, 2026, XORTX Therapeutics (XRTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 6, 2026 and is in week 16. What the four stages mean

Is XORTX Therapeutics in an uptrend?

No. XORTX Therapeutics is in a Stage 4 downtrend. It trades 55.6% below its 200-day average, which is falling.

How far is XORTX Therapeutics from its 52-week high?

XORTX Therapeutics closed at $0.97 on Oct 22, 2026, 73.0% below its 52-week high of $3.59. Its 52-week low is $0.93.

How has XORTX Therapeutics performed over the past year?

As of Oct 22, 2026, XORTX Therapeutics is down 73.3% over the past year and down 66.0% so far in 2026.

Which sector and industry is XORTX Therapeutics in?

XORTX Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.